Whipplewood Advisors LLC Purchases 1,102 Shares of Stryker Co. (NYSE:SYK)

Whipplewood Advisors LLC raised its position in Stryker Co. (NYSE:SYK - Free Report) by 235.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 1,571 shares of the medical technology company's stock after purchasing an additional 1,102 shares during the period. Whipplewood Advisors LLC's holdings in Stryker were worth $585,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of SYK. J. W. Coons Advisors LLC increased its stake in shares of Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after acquiring an additional 26 shares in the last quarter. Mascoma Wealth Management LLC increased its stake in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares in the last quarter. Opal Wealth Advisors LLC raised its holdings in shares of Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after purchasing an additional 28 shares during the period. Lindbrook Capital LLC raised its holdings in shares of Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after purchasing an additional 28 shares during the period. Finally, JFS Wealth Advisors LLC boosted its position in shares of Stryker by 4.4% during the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock worth $247,000 after purchasing an additional 29 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE:SYK traded up $0.19 during mid-day trading on Thursday, reaching $382.74. The company had a trading volume of 893,143 shares, compared to its average volume of 1,331,786. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company's 50-day moving average price is $369.68 and its 200-day moving average price is $376.11. The firm has a market cap of $146.09 billion, a price-to-earnings ratio of 49.32, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business's revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.50 earnings per share. As a group, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's dividend payout ratio is presently 45.41%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on SYK shares. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Evercore ISI decreased their price objective on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Wall Street Zen lowered Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. Finally, Barclays boosted their price target on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $427.30.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.